Related Experiment Videos
Aortic valve replacement with the Toronto SPV bioprosthesis
1Division of Cardiovascular Surgery, Toronto Hospital, Ontario, Canada.
The Journal of Heart Valve Disease
|November 1, 1992
Summary
The Toronto SPV stentless porcine aortic valve replacement (AVR) shows excellent functional and hemodynamic results with a low complication rate. Further follow-up is needed to confirm long-term durability.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Prosthetic Valve Technology
Background:
- Aortic valve replacement (AVR) is a common procedure for severe aortic valve disease.
- Stentless bioprostheses offer potential hemodynamic advantages over stented valves.
- The Toronto SPV is a Dacron-covered stentless porcine aortic prosthesis.
Purpose of the Study:
- To evaluate the safety and efficacy of the Toronto SPV for aortic valve replacement.
- To assess the functional and hemodynamic outcomes of this bioprosthesis.
- To report early complications and survival rates.
Main Methods:
- Implantation of the Toronto SPV in 53 patients undergoing AVR.
- Patient follow-up for a mean of 27 months (range 4-58 months).
- Assessment of valve function, hemodynamics, and complications via Doppler echocardiography and clinical evaluation.
Main Results:
- One operative death; actuarial survival at 4 years was 92% +/- 5%.
- No thromboembolic complications or infective endocarditis reported.
- Excellent effective valve areas, low transvalvular gradients, and minimal aortic insufficiency post-implantation.
Conclusions:
- AVR with the Toronto SPV yields excellent functional and hemodynamic results.
- This bioprosthesis demonstrates a very low rate of valve-related complications.
- The Toronto SPV appears suitable for continued use, pending further durability data.